Trial · NCT07905404
Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip Fracture
NCT07905404, Phase 4, Not yet recruiting, Beth Israel Deaconess Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip Fracture. Trials, record NCT07905404. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905404
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip Fracture
- NCT number
- NCT07905404
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 79 participants, estimated
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Conditions
- Hip Fractures (ICD-10 72.01-72.2), Post Operative Analgesia
- Interventions
- Suzetrigine (Journavx)
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Postoperative Opioid Consumption Rate | From end of surgery through 72 hours postoperatively or hospital discharge, whichever occurs first | Total opioid analgesic administration will be converted to morphine milligram equivalents (MME). Opioid consumption will be expressed as MME per hour during the primary postoperative observation window to account for differences in duration of hospitalization. Lower MME/hour indicates lower opioid consumption. |
| Primary | Cumulative Postoperative Opioid Consumption | From end of surgery through 72 hours postoperatively or hospital discharge, whichever occurs first | Total opioid analgesic administration during the primary postoperative observation window will be converted to cumulative morphine milligram equivalents (MME). Lower cumulative MME indicates lower total opioid exposure. |
| Secondary | Change in Pain Intensity at Rest | Baseline; Post Anesthesia Care Unit (first lucidity); 6, 12, 24, 48, and 72 hours after surgery; and postoperative Days 7, 14, and 28 | Pain intensity will be assessed using the 0-10 Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst possible pain. For participants unable to reliably self-report because of cognitive impairment, the Pain Assessment in Advanced Dementia (PAINAD) scale may be used. Reporting change from baseline and change from prior timepoint is anticipated. Longitudinal pain scores will be evaluated. Lower scores indicate less pain. |
| Secondary | Cumulative Opioid Consumption Through Postoperative Day 14 | From surgery through postoperative Day 14 | All inpatient and reported outpatient opioid use will be converted to morphine milligram equivalents (MME). Cumulative opioid exposure through postoperative Day 14 will be determined. Lower MME indicates lower opioid exposure. |
| Secondary | Proportion of Participants Remaining Rescue Opioid-Free Through 72 Hours | From end of surgery through 72 hours postoperatively or hospital discharge, whichever occurs first | The percentage of participants who do not require rescue opioid analgesia during the first 72 hours after surgery will be determined |
| Secondary | Time to First Rescue Opioid Administration | From end of surgery through 72 hours postoperatively or hospital discharge, whichever occurs first | Time from completion of surgery to the first administration of rescue opioid analgesia will be measured in hours. Participants who do not receive rescue opioids during the observation period will not be analyzed for this outcome measure. |
| Secondary | Hospital Length of Stay | From index hospital admission to discharge, assessed at hospital discharge (anticipated within 7 days of admission) | Hospital length of stay will be calculated as the number of days from hospital admission to hospital discharge. |
| Secondary | 30-Day All-Cause Hospital Readmission | Within 30 days following index hip fracture surgery (postoperative days 0-30) | The percentage of participants experiencing an all-cause hospital readmission within 30 days following hip fracture surgery will be determined. |
| Secondary | Incidence of Postoperative Delirium | From completion of index hip fracture surgery through hospital discharge (anticipated within 7 days postoperatively). | The proportion of participants with postoperative delirium identified through standard-of-care clinical assessment and documentation during the index hospitalization will be determined. |
| Secondary | Incidence of Selected Postoperative Opioid-Related Clinical Events | From completion of index hip fracture surgery through hospital discharge (anticipated within 7 days postoperatively). | The proportion of participants experiencing clinically documented respiratory depression, constipation, falls, or acute cognitive impairment during the index hospitalization will be summarized. |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905404
GET https://conductscience.org/api/trials/v1/NCT07905404/registered